search
Back to results

Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation

Primary Purpose

Inflammation

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Difluprednate Ophthalmic Emulsion
Sponsored by
Sirion Therapeutics, Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Inflammation

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients who have undergone cataract surgery, vitreous surgery or both (including patients who have undergone IOL insertion surgery at the same time)
  • Patients showing an anterior chamber cell score of not less than "2" at a day after surgery
  • Patients aged 20 years or over, irrespective of genders (it is eligible for enrollment when patients' age attains the criterion on the day of consent obtainment)

Exclusion Criteria:

  • Patients who took systemic administration of corticosteroids or immunosuppressive agents, or used ophthalmic ointments of corticosteroids within 1 week before instillation of the investigational drugs;
  • Patients who underwent local injection of corticosteroids in the eyes before instillation of the investigational drugs; (patients who used aqueous preparations within 1 week or patient who used depot preparations within 2 weeks were excluded)
  • Patients who took systemic administration of non-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 3 days before instillation of the investigational drugs;
  • Patients who instilled of corticosteroids, no-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 24 hours before the pre-instillation observation (a day after surgery);
  • Patients who underwent perioperative and/or postoperative intravitreous injection of corticosteroids;
  • Patients who underwent sub-conjunctival injection or sub-Tenon capsule injection of corticosteroids;
  • Patients who have intraocular hemorrhage with a degree that may affect the postoperative evaluations;
  • Patients who underwent gas tamponade at the surgery;
  • Patients with endogenous uveitis;
  • Patients having corneal epithelial detachment or corneal ulcer in the target eye;
  • Patients who are suspected of having viral, bacterial or mycotic keratoconjunctival disorders in the target or opposite eye;
  • Patients with glaucoma or ocular hypertension, or those with past history of IOP increased due to instillation of corticosteroids, or those whose IOP has been controlled by use of ophthalmic antihypertensive agents;
  • Patients showing IOP not less than 25 mmHg a day after surgery;
  • Patients who have allergy to corticosteroid drugs;
  • Patients who are required to wear contact lens during the study period;
  • Patients who are scheduled to undergo surgery of the opposite eye during the study period;
  • Patients who are pregnant or may be pregnant or lactating;
  • Patients who have participated in other clinical studies within 3 months.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    The changes in anterior chamber cell score at day 14 after start of instillation from the baseline level (differences from the baseline score) were compared between the 2 treatment groups.

    Secondary Outcome Measures

    The changes in anterior chamber cell score at days 3 and 7 after start of instillation were compared between the 2 treatment groups.
    The numbers of patients showing an anterior chamber cell score of "0" at days 3, 7 and 14 after start of instillation were compared between the 2 treatment groups.
    The changes in anterior chamber flare score at days 3, 7 and 14 after start of instillation (difference from the baseline score) were compared between the 2 treatment groups.
    The changes in the total scores of subjective symptoms and objective signs at days 3, 7 and 14 after start of instillation (difference from the baseline score) were compared between the 2 treatment groups.

    Full Information

    First Posted
    November 29, 2006
    Last Updated
    November 29, 2006
    Sponsor
    Sirion Therapeutics, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00406341
    Brief Title
    Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation
    Official Title
    Phase 3 Confimatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treament of Postoperative Inflammation
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2006
    Overall Recruitment Status
    Completed
    Study Start Date
    April 2004 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    March 2005 (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Sirion Therapeutics, Inc.

    4. Oversight

    5. Study Description

    Brief Summary
    The purpose of this phase 3 study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of postoperative inflammation.
    Detailed Description
    The objective of this phase 3 study is to assess the efficacy and safety of 0.05% difluprednate ophthalmic emulsion in patients with intraocular postoperative inflammation.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Inflammation

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    200 (false)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Difluprednate Ophthalmic Emulsion
    Primary Outcome Measure Information:
    Title
    The changes in anterior chamber cell score at day 14 after start of instillation from the baseline level (differences from the baseline score) were compared between the 2 treatment groups.
    Secondary Outcome Measure Information:
    Title
    The changes in anterior chamber cell score at days 3 and 7 after start of instillation were compared between the 2 treatment groups.
    Title
    The numbers of patients showing an anterior chamber cell score of "0" at days 3, 7 and 14 after start of instillation were compared between the 2 treatment groups.
    Title
    The changes in anterior chamber flare score at days 3, 7 and 14 after start of instillation (difference from the baseline score) were compared between the 2 treatment groups.
    Title
    The changes in the total scores of subjective symptoms and objective signs at days 3, 7 and 14 after start of instillation (difference from the baseline score) were compared between the 2 treatment groups.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients who have undergone cataract surgery, vitreous surgery or both (including patients who have undergone IOL insertion surgery at the same time) Patients showing an anterior chamber cell score of not less than "2" at a day after surgery Patients aged 20 years or over, irrespective of genders (it is eligible for enrollment when patients' age attains the criterion on the day of consent obtainment) Exclusion Criteria: Patients who took systemic administration of corticosteroids or immunosuppressive agents, or used ophthalmic ointments of corticosteroids within 1 week before instillation of the investigational drugs; Patients who underwent local injection of corticosteroids in the eyes before instillation of the investigational drugs; (patients who used aqueous preparations within 1 week or patient who used depot preparations within 2 weeks were excluded) Patients who took systemic administration of non-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 3 days before instillation of the investigational drugs; Patients who instilled of corticosteroids, no-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 24 hours before the pre-instillation observation (a day after surgery); Patients who underwent perioperative and/or postoperative intravitreous injection of corticosteroids; Patients who underwent sub-conjunctival injection or sub-Tenon capsule injection of corticosteroids; Patients who have intraocular hemorrhage with a degree that may affect the postoperative evaluations; Patients who underwent gas tamponade at the surgery; Patients with endogenous uveitis; Patients having corneal epithelial detachment or corneal ulcer in the target eye; Patients who are suspected of having viral, bacterial or mycotic keratoconjunctival disorders in the target or opposite eye; Patients with glaucoma or ocular hypertension, or those with past history of IOP increased due to instillation of corticosteroids, or those whose IOP has been controlled by use of ophthalmic antihypertensive agents; Patients showing IOP not less than 25 mmHg a day after surgery; Patients who have allergy to corticosteroid drugs; Patients who are required to wear contact lens during the study period; Patients who are scheduled to undergo surgery of the opposite eye during the study period; Patients who are pregnant or may be pregnant or lactating; Patients who have participated in other clinical studies within 3 months.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Shigeaki Ohno
    Organizational Affiliation
    Department of Ophthalmology and Visual Sciences, Graduate School of Medicine, Hokkaido University
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Learn more about this trial

    Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation

    We'll reach out to this number within 24 hrs